Taubert, who was promoted from her role overseeing pharmaceuticals in the Americas in June, runs the drug business that accounted for nearly 50% of the company’s 2017 revenue. In her previous role, she was a key advocate for J&J’s acquisition of Actelion, a $30 billion deal that was completed last summer. In the past 12 months, popular drugs like Darzalex and Imbruvica have led to double-digit growth in Taubert’s pharmaceutical segment and buoyed the company’s total revenue to $76.5 billion.
Company Financials (2017, or most recently completed fiscal year)
|Market Value as of 09/18/18 ($M)||377,034.5|